Business Context and Reporting Period
This Form 8-K, dated April 2, 2026, is filed by Becton, Dickinson and Company (BD). The report addresses the completion of the spin-off of BD's Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, which occurred on February 9, 2026.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains unaudited recast historical financial information. This exhibit presents BD's former Biosciences and Diagnostics Solutions business as discontinued operations to establish a baseline for standalone continuing operations, utilizing non-GAAP measures.
Material Changes
- Corporate Restructuring: BD completed the separation of its Biosciences and Diagnostic Solutions segment and its merger with Waters Corporation.
- Financial Presentation: Historical financial data has been recast to reflect the spun-off business as discontinued operations, altering the historical baseline for continuing operations.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors. It notes that the recast financial information in Exhibit 99.1 includes non-GAAP measures and clarifies that this information is not deemed "filed" under Section 18 of the Exchange Act, nor is it subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited recast financial figures and non-GAAP adjustments.
- Verify the detailed reconciliation between GAAP and non-GAAP measures provided in the exhibit schedules.
- Confirm the impact of the discontinued operations classification on historical comparability.